Skip to main content

Nuechterlein Carole's Form 4 filing

Aligos Therapeutics, Inc. (ALGS) · filed Oct 27, 2023

Accession no.
0001610717-23-000320
Filed
Oct 27, 2023, 4:15 PM ET
Trade date
Oct 25, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $6.00M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Nuechterlein CaroleCIK 0001665133Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 25, 2023Common StockPPurchaseAcquired+7,933,601$0.7568+$6,004,149.2411,025,941Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 25, 2023Common StockPPurchaseAcquired+3,966,800$0.125+$495,8503,966,800Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)